r-ATG

DRUG2 trials

Sponsors

National Heart, Lung, and Blood Institute (NHLBI), Medical College of Wisconsin

Conditions

Aplastic AnemiaSickle Cell Disease

Phase 2

Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia

CompletedNCT00065260

National Heart, Lung, and Blood Institute (NHLBI)Aplastic Anemia

Start: 2003-11-06End: 2016-02-05Updated: 2021-07-21

Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)

CompletedNCT02766465

Medical College of WisconsinSickle Cell Disease

Start: 2017-03-16End: 2023-08-02Updated: 2025-04-18

Related Papers

Hematopoietic Cell Transplant compared with Standard Care in Adolescents and Young Adults with Sickle Cell Disease.

UNC Libraries2024-11-13

Hematopoietic cell transplant compared with standard care in adolescents and young adults with sickle cell disease

Blood Advances2024-10-294 citations

A Qualitative Analysis of State Medicaid Coverage Benefits for Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Patients with Sickle Cell Disease (SCD).

2021-01-296 citations

A Phase II Trial to Compare Allogeneic Transplant Vs. Standard of Care for Severe Sickle Cell Disease: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 1503

Blood2019-11-13

Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study

American Journal of Hematology2019-01-1485 citations

Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia.

2011-11-0876 citations